At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 397 enrolled
Drug / intervention
MM-II dose I +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Single-administration, Multiple-Dose Study to Demonstrate the Efficacy and Safety of MM-II for Treatment of Knee Pain in Subjects With Symptomatic Knee Osteoarthritis
In Brief
A Phase 2 clinical trial evaluating MM-II dose I, MM-II dose II, and 2 other interventions for Osteoarthritis of Knee. Completed, enrolled 397 participants across 25 sites in 3 countries.
Detailed Summary
This is a phase IIb, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of MM-II in subjects with symptomatic knee OA as compared to matching placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis of Knee
CountriesDenmark, Hong Kong, United States
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedAug 2020
Enrollment StartDec 2020
Primary CompletionMay 2022
Study CompletionAug 2022
TodayJul 2026
First PostedAug 10, 2020
Enrollment StartDec 22, 2020
Primary CompletionMay 4, 2022
Study CompletionAug 10, 2022
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 5.9 years ago
Interventions
MM-II dose Idrug
Intra-articular injection
MM-II dose IIdrug
Intra-articular injection
MM-II dose IIIdrug
Intra-articular injection
Placebodrug
Intra-articular injection
Placebodrug
Intra-articular injection
Placebodrug
Intra-articular injection